Aropen 500mg IV Injection

Aropen Injection contains meropenem, a broad-spectrum carbapenem antibiotic used to treat serious bacterial infections in adults and children. It may be prescribed for infections caused by bacteria that are susceptible to meropenem, including infections involving multiple types of bacteria.

Uses of Aropen Injection

Aropen Injection may be used for:

• Pneumonia, including hospital-acquired pneumonia
• Urinary tract infections (UTIs)
• Intra-abdominal infections
• Gynaecological infections, including endometritis and pelvic inflammatory disease
• Skin and skin structure infections
• Meningitis
• Septicaemia
• Pulmonary infections associated with cystic fibrosis
• Suspected bacterial infections in patients with febrile neutropenia

রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন।

How Aropen Injection Works

Meropenem is a carbapenem antibiotic that kills bacteria by interfering with the formation of their cell walls. It binds to bacterial penicillin-binding proteins and prevents the structural processes required for bacterial survival.

Meropenem is stable against many bacterial beta-lactamase enzymes and has activity against a wide range of Gram-positive and Gram-negative bacteria, including both aerobic and anaerobic organisms.

Dosage

The dose and treatment duration depend on the type and severity of the infection, the patient's age and weight, kidney function, and the susceptibility of the causative bacteria. Aropen should only be administered according to a healthcare professional's prescription.

Adults:

• Usual dose: 500 mg to 1 g intravenously every 8 hours.
• Pneumonia, urinary tract infections, gynaecological infections, skin and skin structure infections: commonly 500 mg IV every 8 hours.
• Severe or hospital-acquired pneumonia, peritonitis, septicaemia, and suspected infections in neutropenic patients: commonly 1 g IV every 8 hours.
• Intra-abdominal infections: 500 mg to 1 g IV every 8 hours.
• Pulmonary infections associated with cystic fibrosis: doses up to 2 g every 8 hours may be required.
• Meningitis: 2 g IV every 8 hours.

Children:

• Children aged 3 months to 12 years may receive 10–40 mg/kg IV every 8 hours, depending on the infection and its severity.
• Intra-abdominal infections: 20 mg/kg every 8 hours.
• Cystic fibrosis in children aged 4–18 years: 25–40 mg/kg every 8 hours.
• Meningitis: 40 mg/kg every 8 hours.
• Febrile neutropenia: 20 mg/kg every 8 hours.
• Children weighing more than 50 kg may generally receive adult doses.

Pediatric dosing should be individualized by a qualified healthcare professional.

Administration

Aropen Injection is administered intravenously. It may be given as an IV infusion over approximately 15–30 minutes or as a slow IV bolus over approximately 3–5 minutes, according to the prescribed regimen and formulation.

Side Effects

Aropen is generally well tolerated, but some patients may experience:

• Pain, inflammation, or irritation at the injection site
• Thrombophlebitis
• Skin rash
• Itching
• Hives (urticaria)
• Abdominal pain
• Nausea
• Vomiting
• Diarrhea
• Headache

Serious allergic reactions can occur rarely. Seek immediate medical attention if symptoms such as facial or throat swelling, difficulty breathing, severe rash, or other signs of a severe allergic reaction develop.

Contraindications

Aropen should not be used in patients with a known severe hypersensitivity or allergic reaction to meropenem or any component of the formulation. Patients with a history of serious allergy to beta-lactam antibiotics should inform their doctor before treatment.

Precautions and Warnings

If an allergic reaction occurs during treatment, meropenem should be discontinued and appropriate emergency treatment provided.

Patients with liver disease should be monitored carefully, particularly for changes in liver enzymes and bilirubin levels.

Meropenem should be used carefully in patients with a history of seizures or other neurological disorders, particularly when kidney function is impaired.

Use in Special Populations

Kidney impairment:
The dose generally needs to be reduced in patients with significantly reduced kidney function, particularly when creatinine clearance is below 51 mL/min. Patients receiving hemodialysis should generally receive their dose after dialysis.

Liver impairment:
Dose adjustment is generally not required solely because of impaired liver function, although appropriate monitoring may be necessary.

Elderly patients:
Dose adjustment is generally unnecessary in older adults unless kidney function is significantly reduced.

Children:
The safety and effectiveness of meropenem in infants younger than 3 months have not been sufficiently established.

Pregnancy and Breastfeeding

There are limited controlled data regarding the use of meropenem during pregnancy. It should be used during pregnancy only when clearly indicated and when the expected benefit outweighs potential risks.

Meropenem may pass into breast milk. Breastfeeding mothers should discuss the use of Aropen with their doctor before treatment.

Drug Interactions

Probenecid may reduce the renal elimination of meropenem, increasing its concentration and prolonging its presence in the body.

Meropenem may significantly reduce blood levels of valproic acid, potentially reducing seizure control. Patients taking valproic acid or related medicines should inform their doctor before receiving Aropen.

Always provide your doctor with a complete list of medicines you are taking.

Overdose

An accidental overdose may be more likely to cause problems in patients with impaired kidney function. Symptoms and treatment depend on the amount administered and the patient's condition.

Treatment is generally supportive and focuses on managing symptoms. Meropenem and its metabolites can be removed from the body by hemodialysis in patients with significant kidney impairment.

Therapeutic Class

• Carbapenem antibiotics
• Other beta-lactam antibiotics

Reconstitution and Preparation

Aropen Injection must be reconstituted and prepared by trained healthcare professionals using appropriate sterile techniques.

IV bolus:
The 500 mg or 1 g vial may be reconstituted with sterile water for injection. The solution should be mixed until it becomes clear and colorless to pale yellow.

IV infusion:
The medicine may be prepared using a compatible infusion solution and further diluted, generally in an appropriate volume according to the prescribed administration method.

Compatible infusion fluids may include:

• 0.9% sodium chloride
• 5% or 10% glucose solutions
• Certain glucose-saline combinations
• Mannitol solutions
• Other compatible intravenous fluids specified by the manufacturer

Freshly prepared solutions are preferred. The stability of a reconstituted solution depends on the diluent, storage temperature, and preparation conditions. Follow the manufacturer's preparation and storage instructions for the specific product.

Storage Conditions

Store Aropen Injection vials in a cool, dry place below 30°C, protected from light and moisture. Keep out of reach of children.